|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-2-28
|
|
pubmed:abstractText |
We combined external beam radiotherapy (EBRT) with yttrium-90 ibritumomab tiuxetan ((90)Y-IT) in an attempt to improve therapeutic response in patients with relapsed or refractory bulky follicular lymphoma (RRBFL).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1879-355X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
79
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1124-30
|
|
pubmed:meshHeading |
pubmed-meshheading:20510542-Adult,
pubmed-meshheading:20510542-Aged,
pubmed-meshheading:20510542-Aged, 80 and over,
pubmed-meshheading:20510542-Antibodies, Monoclonal,
pubmed-meshheading:20510542-Blood Cell Count,
pubmed-meshheading:20510542-Disease-Free Survival,
pubmed-meshheading:20510542-Female,
pubmed-meshheading:20510542-Humans,
pubmed-meshheading:20510542-Lymphoma, Follicular,
pubmed-meshheading:20510542-Male,
pubmed-meshheading:20510542-Middle Aged,
pubmed-meshheading:20510542-Platelet Count,
pubmed-meshheading:20510542-Positron-Emission Tomography,
pubmed-meshheading:20510542-Radiotherapy,
pubmed-meshheading:20510542-Radiotherapy Dosage,
pubmed-meshheading:20510542-Recurrence,
pubmed-meshheading:20510542-Tomography, X-Ray Computed,
pubmed-meshheading:20510542-Tumor Burden,
pubmed-meshheading:20510542-Yttrium Radioisotopes
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
